Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy

Stephan Rogalla

Status and phase: Enrolling; Early Phase 1

Conditions: Colorectal Cancer

Treatments: Drug: VGT-309

Study type: Interventional

Funder types: Other

Identifiers

NCT06034197

NCI-2024-01204 (Registry Identifier)

IRB-68096

Details and patient eligibility

About

The purpose of this study is to determine the safety and feasibility of VGT-309 for the visualization of colorectal tumors in real-time using near-infrared (NIR) fluorescence endoscopy. In addition, signatures of 50+ biomarkers will be evaluated in biopsies using CODEX multi-plexing.

Enrollment: 15 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

1. Adult patients with histologically confirmed distal colorectal adenocarcinoma of any stage.

2. Be willing and able to sign the informed consent and comply with study procedures.

3. Are scheduled to undergo a SOC colonoscopy for restaging following radiochemotherapy or are scheduled to receive a SOC colonoscopy in the OR prior to resection

4. Have acceptable kidney and liver functions at study entry as evidenced by:

   1. ALT/AST < 1.5 times the upper limit of normal,
   2. Creatinine clearance (according to Cockcroft-Gault Equation) > 50 mL/min
   3. Total bilirubin < 1.5 times the upper limit of normal

5. Have an ECOG score of 0-2.

6. Be at least 18 years of age.

7. Female participants must be of non-childbearing potential, or, if of childbearing potential be non-pregnant or lactating and agree to use highly effective contraception from screening through 30 days after probe infusion

8. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days post-dose and agree not to donate semen during this waiting period.

9. Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:

   1. Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or
   2. Intrauterine device or intrauterine hormone-releasing system. NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above. They are required to maintain abstinence from screening through Day 30, AND Participants in a same sex relationship, must use a barrier form of contraception (e.g., condom, diaphragm) to protect against the transfer of the study drug in any bodily fluids.

Exclusion Criteria:

Inclusion Criteria:

1. Adult patients with histologically confirmed distal colorectal adenocarcinoma of any stage.

2. Be willing and able to sign the informed consent and comply with study procedures.

3. Are scheduled to undergo a SOC colonoscopy for restaging following radiochemotherapy or are scheduled to receive a SOC colonoscopy in the OR prior to resection

4. Have acceptable kidney and liver functions at study entry as evidenced by:

   1. ALT/AST < 1.5 times the upper limit of normal,
   2. Creatinine clearance (according to Cockcroft-Gault Equation) > 50 mL/min
   3. Total bilirubin < 1.5 times the upper limit of normal

5. Have an ECOG score of 0-2.

6. Be at least 18 years of age.

7. Female participants must be of non-childbearing potential, or, if of childbearing potential be non-pregnant or lactating and agree to use highly effective contraception from screening through 30 days after probe infusion

8. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days post-dose and agree not to donate semen during this waiting period.

9. Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:

   1. Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or
   2. Intrauterine device or intrauterine hormone-releasing system. NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above. They are required to maintain abstinence from screening through Day 30, AND Participants in a same sex relationship, must use a barrier form of contraception (e.g., condom, diaphragm) to protect against the transfer of the study drug in any bodily fluids.

Exclusion Criteria:

1. Pregnant or breastfeeding females
2. They have a known allergy or reaction to ICG, other radiographic contrast agents, or any component of VGT-309.
3. Have congenital long QT syndrome or QTcF > 450ms (males) or >470ms (females) by history or at Screening ECG.
4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.
5. Class 2 or higher obesity, defined by BMI ≥ 35.0.
6. Have any other comorbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

VGT-309

Experimental group

Description:

Subjects will receive an IV infusion of 0.32 mg/kg VGT-309 12 to 36 hours before a standard of care endoscopy procedure.

Treatment:

Drug: VGT-309